Atlanta, USA-based Sciele Pharma, a subsidiary of Japan's Shionogi, says that partner Addrenex Pharmaceuticals has initiated a Phase II clinical trial with ADX415 for the treatment of hypertension. This is a multicenter, double-blind, randomized, placebo-controlled, dose-ranging study that will involve 80 patients. ADX415 is a novel, patented, centrally-acting, alpha-adrenergic receptor agonist, specific to alpha-2 receptors.
Moise Khayrallah, chief executive of Addrenex, said: "while the adrenergic system is best known for its role in triggering the 'fight or flight' response, it is actually a wide-ranging and varied regulator of multiple processes in the body, including blood pressure. We are truly excited about the potential of ADX415, an adrenergic regulator that is designed to target specifically the alpha-2 receptor pathway. We believe this therapeutic area may have a meaningful impact on patients' health and wellbeing."
On July 1, Sciele announced an exclusive agreement with Addrenex to develop and commercialize ADX415, under the terms of which it has the worldwide marketing rights for the product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze